KalVista Pharmaceuticals (KALV) has released an update.
KalVista Pharmaceuticals, Inc. has terminated its Sales Agreement with Cantor Fitzgerald & Co., originally established for the sale of up to $100 million in common stock, effective as of February 14, 2024. Despite the potential for stock offerings under this agreement since May 2021, the company did not sell any shares before issuing the termination notice.
For further insights into KALV stock, check out TipRanks’ Stock Analysis page.
